Overcoming challenges of venous thromboembolism in sickle cell disease treatment

References

• Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013;35(3):352–358.
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011;37(3):226–236.
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirc N Y N 1994. 2004;11(2):129–151.
   Google Scholar
• Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750–760.
   PubMed Web of Science ®Google Scholar
• Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337(22):1584–1590.
   PubMed Web of Science ®Google Scholar
• Gladwin MT. Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016;387(10037):2565–2574.
   PubMed Web of Science ®Google Scholar
• Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653–1662.
   PubMed Web of Science ®Google Scholar
• Charache S, de la Monte S, MacDonald V. Increased blood viscosity in a patient with sickle cell anemia. Blood Cells. 1982;8(1):103–109.
   PubMedGoogle Scholar
• Proença-Ferreira R, Brugnerotto AF, Garrido VT, et al. Endothelial activation by platelets from sickle cell anemia patients. PLOS ONE. 2014;9(2):e89012.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003;115(9):721–728.
   PubMed Web of Science ®Google Scholar
• Hagger D, Wolff S, Owen J, et al. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis Int J Haemost Thromb. 1995;6(2):93–99.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Wun T. Role of the hemostatic system on SCD pathophysiology and potential therapeutics. Hematol Oncol Clin North Am. 2014;28(2):355–374.
   PubMed Web of Science ®Google Scholar
• Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30(4):245–256.
   PubMed Web of Science ®Google Scholar
• Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117(13):3680–3683.
   PubMed Web of Science ®Google Scholar
• Whelihan MF, Lim MY, Mooberry MJ, et al. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J Thromb Haemost JTH. 2016;14(10):1941–1952.
   PubMed Web of Science ®Google Scholar
• Franck PF, Bevers EM, Lubin BH, et al. Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J Clin Invest. 1985;75(1):183–190.
   PubMed Web of Science ®Google Scholar
• Ko RH, Thornburg CD. Venous thromboembolism in children with cancer and blood disorders. Front Pediatr. 2017;5:12.
   PubMed Web of Science ®Google Scholar
• Spentzouris G, Scriven RJ, Lee TK, et al. Pediatric venous thromboembolism in relation to adults. J Vasc Surg. 2012;55(6):1785–1793.
   PubMed Web of Science ®Google Scholar
• Kumar R, Stanek J, Creary S, et al. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Adv. 2018;2(3):285–291.
   PubMed Web of Science ®Google Scholar
• Woods GM, Sharma R, Creary S, et al. Venous thromboembolism in children with sickle cell disease: a retrospective cohort study. J Pediatr. 2018 March;197:186–190.e1.
   Web of Science ®Google Scholar
• Mornand P, Chalard F, Romain A-S, et al. Bilateral pulmonary embolism mimicking acute chest syndrome in an adolescent with sickle cell disease. Arch Pediatr Organe Off Soc Fr Pediatr. 2017;24(7):625–629.
   Google Scholar
• Boechat T de O, Do Nascimento EM, Lobo CL de C, et al. Deep venous thrombosis in children with sickle cell disease. Pediatr Blood Cancer. 2015;62(5):838–841.
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med. 2006;119(10):897.e7–11.
   Web of Science ®Google Scholar
• Novelli EM, Huynh C, Gladwin MT, et al. Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost. 2012;10(5):760–766.
   PubMed Web of Science ®Google Scholar
• Naik RP, Streiff MB, Haywood C, et al. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443–449.
   PubMed Web of Science ®Google Scholar
• Naik RP, Streiff MB, Haywood C, et al. Venous thromboembolism incidence in the cooperative study of sickle cell disease. J Thromb Haemost JTH. 2014;12(12):2010–2016.
   PubMed Web of Science ®Google Scholar
• Yu TT, Nelson J, Streiff MB, et al. Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ(+) thalassemia genotypes. Thromb Res. 2016;141:35–38.
   PubMed Web of Science ®Google Scholar
• Austin H, Lally C, Benson JM, et al. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200(6):620.e1–3.
   PubMed Web of Science ®Google Scholar
• Brunson A, Lei A, Rosenberg AS, et al. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017;178(2):319–326.
   PubMed Web of Science ®Google Scholar
• Manci EA, Culberson DE, Yang Y-M, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123(2):359–365.
   PubMed Web of Science ®Google Scholar
• Ralli E, Zezza L, Caserta D. Pregnancy and venous thromboembolism. Curr Opin Obstet Gynecol. 2014;26(6):469–475.
   PubMed Web of Science ®Google Scholar
• Seaman CD, Yabes J, Li J, et al. Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res. 2014;134(6):1249–1252.
   PubMed Web of Science ®Google Scholar
• Alayed N, Kezouh A, Oddy L, et al. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med. 2014;42:4.
   Web of Science ®Google Scholar
• Ghaji N, Boulet SL, Tepper N, et al. Trends in venous thromboembolism among pregnancy-related hospitalizations, United States, 1994–2009. Am J Obstet Gynecol. 2013;209(5):433.e1–8.
   PubMed Web of Science ®Google Scholar
• James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–1315.
   PubMed Web of Science ®Google Scholar
• Porter B, Key NS, Jauk VC, et al. Impact of sickle hemoglobinopathies on pregnancy-related venous thromboembolism. Am J Perinatol. 2014;31(9):805–809.
   PubMed Web of Science ®Google Scholar
• Shet AS, Wun T. How we diagnose and treat venous thromboembolism in sickle cell disease. Blood. 2018 May;132:1761–1769.
   PubMed Web of Science ®Google Scholar
• Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. North Am J Med Sci. 2014;6(10):491–499.
   PubMedGoogle Scholar
• Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19(2):105–111.
   PubMedGoogle Scholar
• Tivnan P, Billett HH, Freeman LM, et al. Imaging for pulmonary embolism in sickle cell disease: a 17-year experience. J Nucl Med Off Publ Soc Nucl Med. 2018;59(8):1255–1259.
   PubMed Web of Science ®Google Scholar
• Mekontso Dessap A, Deux J-F, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011;184(9):1022–1029.
   PubMed Web of Science ®Google Scholar
• Gopalan D, Delcroix M, Held M. Diagnosis of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160108.
   PubMed Web of Science ®Google Scholar
• Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med Off Publ Soc Nucl Med. 2007;48(5):680–684.
   PubMed Web of Science ®Google Scholar
• Shet AS, Thein SL. Therapeutic advances in sickle cell disease in the last decade. Indian J Med Res. 2017;145(6):708–712.
   PubMedGoogle Scholar
• Wang WC, Dwan K. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2013;11:CD003146. DOI:10.1002/14651858.CD003146.pub2
   PubMed Web of Science ®Google Scholar
• Sumoza A, de Bisotti R, Sumoza D, et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 2002;71(3):161–165.
   PubMed Web of Science ®Google Scholar
• Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319(22):1447–1452.
   PubMed Web of Science ®Google Scholar
• Hyacinth HI, Adams RJ, Greenberg CS, et al. Effect of chronic blood transfusion on biomarkers of coagulation activation and thrombin generation in sickle cell patients at risk for stroke. PLOS ONE. 2015;10(8):e0134193.
   PubMed Web of Science ®Google Scholar
• Koc A, Gumruk F, Gurgey A. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol. 2003;20(6):429–434.
   PubMed Web of Science ®Google Scholar
• Mahfoudhi E, Lecluse Y, Driss F, et al. Red cells exchanges in sickle cells disease lead to a selective reduction of erythrocytes-derived blood microparticles. Br J Haematol. 2012;156(4):545–547.
   PubMed Web of Science ®Google Scholar
• Nébor D, Romana M, Santiago R, et al. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica. 2013;98(6):862–867.
   PubMed Web of Science ®Google Scholar
• Brunetta DM, De Santis GC, Silva-Pinto AC, et al. Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia. Acta Haematol. 2015;133(3):287–294.
   PubMedGoogle Scholar
• Curative treatment for severe sickle cell disease: allogeneic transplantation – Hematology & oncology. [cited 2018 Oct 8]. Available from: http://www.hematologyandoncology.net/archives/april-2015/curative-treatment-for-severe-sickle-cell-disease-allogeneic-transplantation/
   Google Scholar
• Qaseem A, Chou R, Humphrey LL, et al. Clinical guidelines committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;155(9):625–632.
   PubMed Web of Science ®Google Scholar
• Kelley D, Jones LT, Wu J, et al. Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease. J Thromb Thrombolysis. 2017;43(4):463–468.
   PubMed Web of Science ®Google Scholar
• Morales E, Villanueva GI, Hsu LL, et al. Should sickle cell disease be among the risk factors for use of thromboprophylaxis in adolescents and young adults? Blood. 2016;128(22):4855–4856.
   Web of Science ®Google Scholar
• Shah N, Landi D, Shah R, et al. Complications of implantable venous access devices in patients with sickle cell disease. Am J Hematol. 2012;87(2):224–226.
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Thibodeaux SR, Jackups R. Vascular access for red blood cell exchange. Transfusion (Paris). 2018;58(S1):569–579.
   Google Scholar
• Putensen D, Pilcher L, Collier D, et al. Ultrasound-guided peripheral deep vein cannulation to perform automated red cell exchange-A pilot study in a single centre. J Clin Apheresis. 2016;31(6):501–506.
   PubMed Web of Science ®Google Scholar
• Kalantari K. The choice of vascular access for therapeutic apheresis. J Clin Apheresis. 2012;27(3):153–159.
   PubMed Web of Science ®Google Scholar
• Evidence-based management of sickle cell disease: expert panel report, 2014 | National Heart, Lung, and Blood Institute (NHLBI). Available from: [cited 2018 Oct 8]. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
   Google Scholar
• Coppola A, Tufano A, Cerbone AM, et al. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost. 2009;35(7):683–694.
   PubMed Web of Science ®Google Scholar
• MacCallum P, Bowles L, Keeling D. Diagnosis and management of heritable thrombophilias. BMJ. 2014;349:g4387.
   PubMedGoogle Scholar
• Salvaggio JE, Arnold CA, Banov CH. Long-term anticoagulation in sickle-cell disease. N Engl J Med. 1963;269(4):182–186.
   PubMed Web of Science ®Google Scholar
• Schnog JB, Kater AP, Gillavry MRM, et al. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol. 2001;68(3):179–183.
   PubMed Web of Science ®Google Scholar
• Chaplin JH, Monroe MC, Malecek AC, et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989;66(9):574–584.
   PubMedGoogle Scholar
• Cabannes R, Lonsdorfer J, Castaigne JP, et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl. 1984;15:199–212.
   PubMedGoogle Scholar
• Semple MJ, Al-Hasani SF, Kioy P, et al. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost. 1984;51(3):303–306.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625–635.
   PubMed Web of Science ®Google Scholar
• Thromboembolism and inherited thrombophilias in pregnancy –ACOG. cited 2018 Oct 8. Available from: https://www.acog.org/Womens-Health/Thromboembolism-and-Inherited-Thrombophilias-in-Pregnancy
   Google Scholar
• Alsayegh F, Al-Jassar W, Wani S, et al. Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf. Curr Vasc Pharmacol. 2016;14(4):368–373.
   PubMed Web of Science ®Google Scholar
• Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359(19):2025–2033.
   PubMed Web of Science ®Google Scholar
• Mortality among women with sickle cell disease admitted for delivery, California 2004–2014 | Blood Journal. [cited 2018 Oct 8]. Available from: http://www.bloodjournal.org/content/128/22/2332?sso-checked=true
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Strykowski R, Scarpato B, Patel J, et al. Recurrent venous thromboembolism is common in adults with sickle cell disease. B60. HERE WE CLOT AGAIN: CLINICAL STUDIES IN PE AND CTEPH. American Thoracic Society International Conference Abstracts; 2018; American Thoracic Society. p. A3762–A3762. DOI:10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3762
   Google Scholar
• Bhat S, Han J. Outcomes of rivaroxaban use in patients with sickle cell disease. Ann Pharmacother. 2017;51(4):357–358.
   PubMed Web of Science ®Google Scholar
• Patel A, Williams H, Baer MR, et al. Use of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism is associated with a significant decrease in incidence of bleeding compared to vitamin K antagonists and low-molecular-weight heparins. Blood. 2017;130(Suppl 1):978–979.
   Google Scholar
• Stone RH, Bress AP, Nutescu EA, et al. Upper-extremity deep-vein thrombosis: a retrospective cohort evaluation of thrombotic risk factors at a University Teaching Hospital Antithrombosis Clinic. Ann Pharmacother. 2016;50(8):637–644.
   PubMed Web of Science ®Google Scholar
• Roberts MZ, Gaskill GE, Kanter-Washko J, et al. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. J Thromb Thrombolysis. 2018;45(4):512–515.
   PubMed Web of Science ®Google Scholar
• EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Oral rivaroxaban for symptomatic venous thromboembolism | NEJM. [cited 2018 Oct 8]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1007903
   Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Lanzkron S, Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol. 2011;4(6):597–606.
   PubMed Web of Science ®Google Scholar
• Adams RJ, Cox M, Ozark SD, et al. Coexistent sickle cell disease has no impact on the safety or outcome of lytic therapy in acute ischemic stroke: findings from get with the guidelines-stroke. Stroke. 2017;48(3):686–691.
   PubMed Web of Science ®Google Scholar